Insight

Initial Data Shows that PTAB Is Not a ῾Death Squadʼ for Biologic Drug Patents

The March 2017 statistics issued by PTAB report that across all technologies, all challenged patent claims are found patentable in only 19 percent of inter partes review (IPR) final written decisions.

Biologic Drug Patents
CB

Corinne E. Atton and April M. Breyer

June 29, 2017 10:05 AM

The March 2017 statistics issued by the United States Patent Trial and Appeal Board (PTAB) report that across all technologies, all challenged patent claims are found patentable in only 19 percent of inter partes review (IPR) final written decisions.1 This is an improvement over a low point of in only 13 percent of decisions between late 2015 and early 2016,2 but this percentage does little to assuage concerns that PTAB is a patent “death squad.”3 But there is good news for the pharmaceutical industry. The data concerning drug patents is more favorable: a smaller percentage of drug patent IPRs are instituted, and a higher percentage of drug patent IPRs survive final written decisions with all instituted claims intact. The initial data for IPR challenges to patents that are identified as reading on CDER-listed Biologic Drugs (Biologic Drug IPRs) is also looking promising. While the dataset remains very small, Biologic Drug patents are holding up in institutions and in final written decisions.

As of March 31, 2017, PTAB reports that there were 4,563 resolved IPRs.4 Of these, 222 concerned patents were listed in the U.S. Food and Drug Administration Orange Book (Orange Book IPRs) and 29 concerned biologic drug patents.5 Looking at the total number of resolved IPRs, 53 percent were instituted and 35 percent reached final written decision. For Orange Book IPRs, these numbers are 44 percent and 38 percent; Biologic Drug IPRs are 41 percent and 28 percent.

Considering just these two stages of PTAB determination—institution decisions and final written decisions—PTAB found that at least some challenged claims were patentable (in that PTAB did not institute IPR on these claims or PTAB found instituted claims not unpatentable in a final written decision) in 41 percent of the total number of resolved IPRs. This number marks the most significant difference between the data across technologies. The comparative number for Orange Book and Biologic Drug IPRs is 60 percent and 45 percent respectively, comprising a combined total of 58 percent. It is also noteworthy that a higher percentage of Biologic Drug IPRs settled before an institution decision: 21 percent of the total number of Biologic Drug IPRs, compared to only 12 percent of the total number of Orange Book IPRs.6 In other words, proportionately fewer Biologic Drug IPRs reached an institution decision.

In short, the statistics concerning drug patent challenges are optimistic. Orange Book and Biologic Drug patents are faring better in IPRs than patents across all technologies, and the initial data for Biologic Drug IPRs is looking promising: a higher percentage of challenges have settled before an institution decision, and a higher percentage of challenged claims have survived IPR unscathed as patentable.

----------------

1https://www.uspto.gov/sites/default/files/documents/AIA%20Statistics_March2017.pdf
2 See September 2015 through February 2016 PTAB statistics at https://www.uspto.gov/patents-application-process/appealing-patent-decisions/statistics/aia-trial-statistics.
3See Randall Rader, C.J., Fed. Cir., Address at the American Intellectual Property Law Association Annual Meeting (Oct. 25, 2013). (“You’ve got an agency with 7,000 people giving birth to property rights, and then you’ve got, in the same agency, 300 or so people on the back end … acting as death squads, kind of killing property rights.”)
4https://www.uspto.gov/sites/default/files/documents/AIA%20Statistics_March2017.pdf
5Data relating to Orange Book and Biologic Drug IPRs is obtained from proprietary databases maintained by Fitzpatrick Cella Harper and Scinto. Data relating to Biologic Drug IPRs is available here: http://www.biologicshq.com/.
6A further 7 percent of the total number of Biologic Drug IPRs settled after institution, resulting in a total of 28 percent that settled prior to a final written decision. A further 5 percent of the total number of Orange Book IPRs settled after institution, resulting in a total of 17 percent that settled prior to a final written decision.

Trending Articles

Introducing the 2026 Best Lawyers Awards in Australia, Japan, New Zealand and Singapore


by Jennifer Verta

This year’s awards reflect the strength of the Best Lawyers network and its role in elevating legal talent worldwide.

2026 Best Lawyers Awards in Australia, Japan, New Zealand and Singapore

Revealing the 2026 Best Lawyers Awards in Germany, France, Switzerland and Austria


by Jamilla Tabbara

These honors underscore the reach of the Best Lawyers network and its focus on top legal talent.

map of Germany, France, Switzerland and Austria

Effective Communication: A Conversation with Jefferson Fisher


by Jamilla Tabbara

The power of effective communication beyond the law.

 Image of Jefferson Fisher and Phillip Greer engaged in a conversation about effective communication

The 2025 Legal Outlook Survey Results Are In


by Jennifer Verta

Discover what Best Lawyers honorees see ahead for the legal industry.

Person standing at a crossroads with multiple intersecting paths and a signpost.

The Best Lawyers Network: Global Recognition with Long-term Value


by Jamilla Tabbara

Learn how Best Lawyers' peer-review process helps recognized lawyers attract more clients and referral opportunities.

Lawyers networking

Jefferson Fisher: The Secrets to Influential Legal Marketing


by Jennifer Verta

How lawyers can apply Jefferson Fisher’s communication and marketing strategies to build trust, attract clients and grow their practice.

Portrait of Jefferson Fisher a legal marketing expert

Is Your Law Firm’s Website Driving Clients Away?


by Jamilla Tabbara

Identify key website issues that may be affecting client engagement and retention.

Phone displaying 'This site cannot be reached' message

A Guide to Workers' Compensation Law for 2025 and Beyond


by Bryan Driscoll

A woman with a laptop screen reflected in her glasses

Medical Malpractice Reform Trends in Texas, Utah, Georgia and SC


by Bryan Driscoll

A fresh wave of medical malpractice reform is reshaping the law.

Medical Malpractice Reform Trends hed

Why Jack Dorsey and Elon Musk Want to 'Delete All IP Law'


by Bryan Driscoll

This Isn’t Just a Debate Over How to Pay Creators. It’s a Direct Challenge to Legal Infrastructure.

Elon Musk and Jack Dorsey standing together Infront of the X logo

Best Lawyers Launches CMO Advisory Board


by Jamilla Tabbara

Strategic counsel from legal marketing’s most experienced voices.

Group photo of Best Lawyers CMO Advisory Board members

Changes in California Employment Law for 2025


by Laurie Villanueva

What employers need to know to ensure compliance in the coming year and beyond

A pair of hands holding a checklist featuring a generic profile picture and the state of California

Common Law Firm Landing Page Problems to Address


by Jamilla Tabbara

Identify key issues on law firm landing pages to improve client engagement and conversion.

Laptop showing law firm landing page analytics

New Employment Law Recognizes Extraordinary Stress Is Everyday Reality for NY Lawyers


by Bryan Driscoll

A stressed woman has her head resting on her hands above a laptop

Best Lawyers Introduces Smithy AI


by Jamilla Tabbara

Transforming legal content creation for attorneys and firms.

Start using Smithy AI, a content tool by Best Lawyers

How to Create High-Converting Landing Pages for Your Law Firm


by Jamilla Tabbara

Learn how to create high-converting law firm landing pages that drive client engagement and lead generation.

Laptop screen displaying website tools to improve client conversion rates